Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd CANF said that the topline data from its Phase 3 Comfort study of Piclidenoson in severe plaque psoriasis would be released in Q2 2022. 

• Earlier, the data were anticipated in Q1 of 2022.
• The study enrolled more than 400 patients across 30 sites in Europe, Israel, and Canada.
• Piclidenoson is an A3 adenosine receptor agonist (A3AR) small molecule that inhibits interleukin-17 and interleukin-23, both pivotal for the formation of skin lesions. 
• Piclidenoson has also recently been shown to induce the death of pathological skin cells.
• The Comfort study's primary endpoint is the proportion of patients who achieve a PASI score response of ≥75% (PASI 75) vs. placebo at week 16. Secondary endpoints include non-inferiority to Amgen Inc's AMGN Otezla (apremilast).
• Also See: Can-Fite Shares Rally As Namodenoson Clears All Cancer Lesions In Liver Cancer Patient.
• Price Action: CANF shares are down 7.21% at $1.03 during the premarket session on the last check Tuesday.